entertainment -WSS

entertainment

author：comprehensive 2025-10-01 12:54:53 - browse：3318

Adam's take main illustration — Molly Ferguson/STAT

The eye disease physician in charge of a committee that flagged a rare but severe side effect involving a newly approved drug from Apellis Pharmaceuticals has financial ties to a competing drugmaker. The conflict raises questions about his supervision of an emerging safety issue for patients and its impact on the financial health of Apellis.

Peter Kaiser, a retinal disease expert who runs the Cole Eye Institute at the Cleveland Clinic, failed to report consulting fees and stock ownership in Iveric Bio on a financial disclosure form maintained by the American Society of Retina Specialists, or ASRS. Iveric Bio is developing a treatment for geographic atrophy, a common, age-related cause of vision loss and the same indication for which the Apellis drug was approved.

The financial conflict, which was undisclosed until after Kaiser was contacted about it by STAT, is relevant because Kaiser also chairs a committee of the ASRS responsible for monitoring the safety of retina drugs and devices. On July 15, Kaiser’s committee sent a letter to member doctors, alerting them to reports of eye inflammation in people receiving injections of Syfovre, the treatment recently approved and launched by Apellis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： The science behind Janet Jackson's pregnancy at 49

WSS

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

FDA's naming rule on biosimilars has undermined competition

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Washington mulls new rules to avert another Change Healthcare

Colonoscopy at 40? Study finds a possible benefit

Disclosing genetic information: not as worrisome as once feared

Wikipedia

entertainment

leisure time

State Dept. review finds Biden bears some blame for Afghanistan failures

Disclosing genetic information: not as worrisome as once feared

Affirmative action in medical school literally saved lives

Vertex Pharmaceuticals may move headquarters in Boston

Dobbs anniversary: the lost opportunity of abortion as health care

Disclosing genetic information: not as worrisome as once feared

Cancer drug shortages should be causing more outrage

The science behind Janet Jackson's pregnancy at 49

Affirmative action in medical school literally saved lives

States should stop sabotaging methadone treatment reform

focus

Readout LOUD podcast: mifepristone case, GLP

Covid vaccine financial winners and losers, from Pfizer to Novavax

There's no autism epidemic. It's an autism diagnosis epidemic

The story of mRNA: From a loose idea to a tool that may help curb Covid

Decaf coffee targeted by food safety group under obscure FDA rule

Washington mulls new rules to avert another Change Healthcare

Wikipedia

explore

focus

focus